Kadans Science Partner welcomes global molecular diagnostics innovator, Sense Biodetection (Sense), to The Science Quadrant at Abingdon Science Park, Oxfordshire.  The move doubles Sense’s existing laboratory capacity, enhancing the firm’s capability to accelerate development of a broad test menu on its Veros™ molecular platform.

Abingdon Science Park is one of the leading locations in Oxfordshire for science and technology innovation. Set in an attractive, landscaped location to the south of Oxford the park offers a variety of accommodation to suit companies at all stages of their development. Abingdon Science Park is home to a fantastic cluster of R&D and Science related companies, driving its own ecosystem. Kadans is continuously bringing forward new laboratory accommodation on the park to support the needs of growing businesses in Oxfordshire.

Kadans Science Partner worked closely with our partners Bulb Laboratories, specialist laboratory design & delivery service providers, to provide a fully fitted turnkey solution for Sense. Kadans & Bulb worked closely with Sense to understand their business and real estate requirements. We were able to advise and provide Sense fully operational laboratories suitable for their needs.

Katie Nelson, Commercial Asset Manager at Kadans Science Partner: “We are so pleased to have Sense join our rapidly expanding diagnostics cluster here at The Science Quadrant. They are a great addition to the park and ecosystem of the area. They are a fantastic example of what Kadans can do working with our tenants to provide them best in class facilities.”

Edward Joslin, Development Director at Kadans Science Partner: “This has been an amazing opportunity to transform and refresh the building into a new use. The project has been a resounding success and true team effort being delivered on time and within budget.”

Sense Founder and Chief Business Development Officer, Dr Harry Lamble said, “Kadans and Bulb Laboratories’ professionalism and expertise has been instrumental in delivering this high specification space to accommodate our growing and talented team of scientific innovators.  This move complements our global strategy to launch a portfolio of highly accurate, point-of-care tests for a range of diseases – stretching far beyond the forthcoming launch of the Veros™ COVID-19 test.”